Galectin Therapeutics Files 2024 Proxy Statement
Ticker: GALT · Form: DEF 14A · Filed: Dec 3, 2024 · CIK: 1133416
| Field | Detail |
|---|---|
| Company | Galectin Therapeutics INC (GALT) |
| Form Type | DEF 14A |
| Filed Date | Dec 3, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: GALT
TL;DR
Galectin Therapeutics (GALT) filed its proxy statement for the Jan 23, 2025 meeting. Vote your shares!
AI Summary
Galectin Therapeutics Inc. filed a DEF 14A proxy statement on December 3, 2024, for its annual meeting scheduled for January 23, 2025. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and operates in the pharmaceutical preparations industry. The filing details information related to the solicitation of proxies for the upcoming shareholder meeting.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposed resolutions and director elections, allowing them to make informed voting decisions.
Risk Assessment
Risk Level: low — A DEF 14A filing is a routine disclosure document for public companies regarding their annual shareholder meetings and does not inherently present new financial risks.
Key Players & Entities
- GALECTIN THERAPEUTICS INC (company) — Registrant
- PRO PHARMACEUTICALS INC (company) — Former Company Name
- 20250123 (date) — Annual Meeting Date
- 20241203 (date) — Filing Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is a document that a company must provide to its shareholders before their annual meeting. It contains important information about the matters to be voted on, such as the election of directors, executive compensation, and other corporate proposals.
When is Galectin Therapeutics Inc.'s annual meeting scheduled?
Galectin Therapeutics Inc.'s annual meeting is scheduled for January 23, 2025.
What was Galectin Therapeutics Inc.'s former company name?
Galectin Therapeutics Inc.'s former company name was Pro Pharmaceuticals Inc.
On what date was this DEF 14A filing submitted?
This DEF 14A filing was submitted on December 3, 2024.
In which state is Galectin Therapeutics Inc. incorporated?
Galectin Therapeutics Inc. is incorporated in Nevada (NV).
Filing Stats: 4,537 words · 18 min read · ~15 pages · Grade level 11 · Accepted 2024-12-03 08:03:46
Key Financial Figures
- $0.001 — 8,075 shares of common stock, par value $0.001 per share (“Common Stock”
- $0.01 — Convertible Preferred Stock, par value $0.01 per share (“Series A Prefer
Filing Documents
- ny20035571x1_def14a.htm (DEF 14A) — 799KB
- logo_galectin.jpg (GRAPHIC) — 26KB
- ny20035571x1_pvpchart1.jpg (GRAPHIC) — 138KB
- ny20035571x1_pvpchart2.jpg (GRAPHIC) — 118KB
- sig_jlewis.jpg (GRAPHIC) — 13KB
- sig_jwcallicutt.jpg (GRAPHIC) — 17KB
- ny20035571x1_pc01.jpg (GRAPHIC) — 541KB
- ny20035571x1_pc02.jpg (GRAPHIC) — 514KB
- 0001140361-24-048239.txt ( ) — 2679KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT     6 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE     8 PROPOSAL NO. 1 ELECTION OF DIRECTORS     9 EXECUTIVE OFFICERS     13 CORPORATE GOVERNANCE     13 DIRECTOR COMPENSATION     21
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION     23 SUMMARY COMPENSATION TABLE     28 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END 2023     29 PROPOSAL NO. 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS     35 FEES PAID TO CHERRY BEKAERT LLP     35 PROPOSALS OF STOCKHOLDERS     36 ANNUAL REPORT     37 HOW TO ATTEND THE 2024 ANNUAL MEETING     38         i TABLE OF CONTENTS GALECTIN THERAPEUTICS INC. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, Georgia 30071 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on January 23, 2025 This proxy statement contains information about the 2024 annual meeting of stockholders (“2024 Annual Meeting”) of Galectin Therapeutics Inc. (referred to in this proxy statement as “Galectin”, “Galectin Therapeutics”, “the Company”, “we”, “our” or “us”). The 2024 Annual Meeting will be held virtually over the internet on Thursday, January 23, 2025, beginning at 11:00 a.m. Eastern Standard Time, at www.virtualshareholdermeeting.com/GALT2024. Online access begins at 10:45 a.m. on the date of the 2024 Annual Meeting. Due to the cost savings and other efficiencies resulting from conducting a virtual meeting, the Company is conducting an online-only format for the 2024 annual meeting. Stockholders will be able to listen, vote, and submit questions from their home or any remote location with internet connectivity. The 2024 Annual Meeting has been designed to provide the same rights to participate as you would have at an in-person meeting. Information on how to participate in this year’s virtual meeting can be found on page 38 . This proxy statement is furnished in connection with the solicitation of proxies by our Board of Directors for
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth, as of October 1, 2024, certain information concerning the beneficial ownership of our Common Stock and Series A Preferred Stock by (i) each person known by us to own beneficially five percent (5%) or more of the outstanding shares of each class, (ii) each of our directors, new director nominee and named executive officers, and (iii) all of our executive officers, directors and new director nominee as a group. The table also sets forth, in its final column, the combined voting power of the voting securities on all matters presented to the stockholders for their approval at the 2024 Annual Meeti